FrancophonIA/ELRC3.0 huggingface dataset:
English: In clinical studies 99.2% to 100% who received Gardasil 9 became seropositive for antibodies against all 9 vaccine types by Month 7 across all groups tested.
Danish: I kliniske studier blev 99,2% til 100% af dem, som fik Gardasil 9, seropositive for antistoffer mod alle 9 vaccinetyper ved måned 7 på tværs af alle de testede grupper.
English: In 16- through 26- year-old men (N=4,055) efficacy against HPV 6, 11, 16 or 18-related diseases was 74.9% (95% CI: 8.8, 95.4) for AIN 2/3 (median duration of follow-up of 2.15 years), 100.0% (95% CI: -52.1, 100) for penile/perineal/perianal intraepithelial neoplasia (PIN) 1/2/3, and 89.3% (95% CI: 65.3, 97.9) for genital warts (median duration of follow-up of 4 years).
Danish: Hos mænd på 16-26 år (N=4.055) var effekten mod HPV 6-, 11-, 16- eller 18-relaterede sygdomme 74,9% (95% CI: 8,8; 95,4) for AIN 2/3 (median varighed af opfølgning på 2,15 år), 100,0% (95% CI: -52,1; 100) for penil/perineal/perianal intraepitelial neoplasi (PIN) 1/2/3 og 89,3% (95% CI: 65,3; 97,9) for kondylomer (median varighed af opfølgning på 4 år).
English: Protocol 010 evaluated the immunogenicity of 2 doses of Gardasil 9 in girls and boys aged 9 to 14 years and 3 doses of Gardasil 9 in girls aged 9 to 14 years and women aged 16 to 26 years (N=1,518; 753 girls; 451 boys and 314 women).
Danish: Protokol 010 evaluerede immunogenicitet af 2 doser Gardasil 9 hos piger og drenge i alderen 9 til 14 år, og 3 doser Gardasil 9 hos piger i alderen 9 til 14 år og kvinder i alderen 16 til 26 år (N=1.518; 753 piger; 451 drenge og 314 kvinder).
English: Protocol 003 evaluated immunogenicity of Gardasil 9 in men aged 16 to 26 years and women aged 16 to 26 years (N=2,515:1,103 Heterosexual Men [HM]; 313 Men Who Have Sex with Men [MSM]; and 1,099 women receiving Gardasil 9).
Danish: Protokol 003 evaluerede immunogeniciteten af Gardasil 9 hos mænd i alderen 16 til 26 år og kvinder i alderen 16 til 26 år (N=2.515; 1.103 heteroseksuelle mænd [HM]; 313 mænd som har sex med mænd [MSM]; og 1.099 kvinder som fik Gardasil 9).
English: HPV Type 11 and 18 L1 protein
Danish: HPV-type 11 og 18 L1-protein
English: Gardasil 9 induced robust anti-HPV 6, anti-HPV 11, anti-HPV 16, anti-HPV 18, anti-HPV 31, anti-HPV 33, anti-HPV 45, anti-HPV 52, and anti-HPV 58 responses measured at Month 7, in
Danish: Gardasil 9 inducerede robuste anti-HPV 6, anti-HPV 11, anti-HPV 16, anti-HPV 18, anti-HPV 31, anti-HPV 33, anti-HPV 45, anti-HPV 52 og anti-HPV 58 responser målt ved måned 7, i Protokol 001, 002, 004, 005, 007 og GDS01C/Protokol 009.
English: Keep the pre-filled syringe in the outer carton in order to protect from light.
Danish: Opbevar den forfyldte sprøjte i den ydre karton for at beskytte mod lys.
English: Gardasil 9 injection IM
Danish: Gardasil 9 injektion i.m.
English: Adsorbed on amorphous aluminium hydroxyphosphate sulfate adjuvant (0.5 milligrams Al).
Danish: adsorberet på amorf aluminiumhydroxyphosphatsulfat-adjuvans (0,5 mg Al).
English: Injection-site cellulitis
Danish: Cellulitis på injektionsstedet
English: Gardasil 9 suspension for injection in a pre-filled syringe Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)
Danish: Gardasil 9 suspension til injektion i en forfyldt sprøjte Human papillomavirusvaccine, 9-valent (rekombinant, adsorberet)
English: Gardasil 9 suspension for injection Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)
Danish: Gardasil 9 suspension til injektion Human papillomavirusvaccine, 9-valent (rekombinant, adsorberet)
English: Protocol 002 evaluated immunogenicity of Gardasil 9 in girls and boys aged 9 to 15 years and women aged 16 to 26 years (N=3,066: 1,932 girls; 666 boys; and 468 women receiving Gardasil 9).
Danish: Protokol 002 evaluerede immunogeniciteten af Gardasil 9 hos piger og drenge i alderen 9 til 15 år og kvinder i alderen 16 til 26 år (N=3.066: 1.932 piger; 666 drenge; og 468 kvinder som fik Gardasil 9).
English: It is recommended that individuals who receive a first dose of Gardasil 9 complete the vaccination course with Gardasil 9 (see section 4.4).
Danish: Det anbefales, at personer, som har fået Gardasil 9 som første dosis, gennemfører vaccinationsprogrammet med Gardasil 9 (se pkt.
English: What Gardasil 9 contains
Danish: Gardasil 9 indeholder
English: HPV 31-, 33-, 45-, 52-, 58-related VIN 2/3, VaIN 2/3
Danish: HPV 31-, 33-, 45-, 52-, 58-relateret VIN 2/3, VaIN 2/3
English: *The PPI population consisted of individuals who received all three vaccinations within predefined day ranges, did not have major deviations from the study protocol, met predefined criteria for the interval between the Month 6 and Month 7 visit, seronegative to the relevant HPV type(s) (types 6, 11, 16, and 18) prior to dose 1, and among 16 to 26 year old women, were PCR negative to the relevant HPV type(s) prior to dose 1 through one month postdose 3 (Month 7).
Danish: Mænd i alderen 16 til 26 år *PPI-populationen bestod af personer, der fik alle 3 vaccinationer inden for et prædefineret interval af dage, ikke afveg fra studieprotokollen i større grad, opfyldte prædefinerede kriterier for intervallet mellem måned 6- og måned 7-besøget, var seronegative over for de(n) relevante HPV-type(r) (type 6, 11, 16 og 18) før dosis 1 og blandt 16- til 26-årige kvinder var PCR-negative over for de(n) relevante HPV-type(r) før dosis 1 til og med én måned efter dosis 3 (måned 7).
English: The efficacy of Gardasil 9 against cervical definitive therapy (including loop electrosurgical excision procedure [LEEP] or conisation) related to vaccine HPV types compared to qHPV vaccine was 90.7% (95% CI 76.3, 97.0) with 4/6,016 versus 43/6,018 cases.
Danish: Effekten af Gardasil 9 mod cervikal definitiv terapi (inklusive LEEP (Loop Electro-Excision Procedure) eller konisering) relateret til vaccine-HPV-typerne sammenlignet med qHPV-vaccine var 90,7% (95% CI 76,3; 97,0) med 4/6.016 versus 43/6.018 tilfælde.
English: However, in individuals who are already infected with one or more of the vaccine HPV types, Gardasil 9 can still protect against diseases associated with the other HPV types in the vaccine.
Danish: Dog kan Gardasil 9 stadigvæk beskytte personer, som allerede er smittet med en eller flere vaccine-HPV-typer, mod de andre HPV-typer i vaccinen.
English: If you have any further questions on the use of this vaccine, ask your doctor or pharmacist.
Danish: Spørg lægen eller apotekspersonalet, hvis der er mere, du vil vide om brugen af denne vaccine.
English: 30 micrograms
Danish: 30 mikrogram
English: Few individuals (0.1%) discontinued due to adverse experiences.
Danish: Kun få personer (0,1%)
English: B. Tabulated summary of adverse reactions
Danish: B. Oversigt over bivirkninger i tabelform
English: Fainting, sometimes accompanied by falling, can occur (mostly in adolescents) following any needle injection.
Danish: Der er nogen (mest unge), der besvimer og nogle gange falder efter en nåleinjektion.
English: 40 micrograms
Danish: 40 mikrogram
English: The efficacy of Gardasil 9 against CIN 2 and worse related to vaccine HPV types compared to qHPV vaccine was 94.4% (95% CI 78.8, 99.0) with 2/5,952 versus 36/5,947 cases.
Danish: Effekten af Gardasil 9 mod CIN 2 og værre relateret til vaccine-HPV-typerne sammenlignet med qHPV-vaccine var 94,4% (95% CI 78,8; 99,0) med 2/5.952 versus 36/5.947 tilfælde.
English: The efficacy of Gardasil 9 against cervical biopsy related to vaccine HPV types compared to qHPV vaccine was 95.9% (95% CI 92.7, 97.9) with 11/6,016 versus 262/6,018 cases.
Danish: Effekten af Gardasil 9 mod cervikal biopsi relateret til vaccine-HPV-typerne sammenlignet med qHPV-vaccine var 95,9% (95% CI 92,7; 97,9) med 11/6.016 versus 262/6.018 tilfælde.
English: The efficacy of Gardasil 9 against CIN 3 related to vaccine HPV types compared to qHPV vaccine was 100% (95% CI 46.3, 100.0) with 0/5,952 versus 8/5,947 cases.
Danish: Effekten af Gardasil 9 mod CIN 3 relateret til vaccine-HPV-typerne sammenlignet med qHPV-vaccine var 100% (95% CI 46,3; 100,0) med 0/5.952 versus 8/5.947 tilfælde.
English: HPV 31-, 33-, 45-, 52-, 58-related CIN 2/3 or AIS
Danish: HPV 31-, 33-, 45-, 52-, 58-relateret CIN 2/3 eller AIS
English: The GMTs to HPV types 6, 11, 16, 18 were higher than in the population who had not previously received qHPV vaccine in other studies whereas the
Danish: GMT'erne over for HPV-type 6, 11, 16 og 18 var højere end i den population, som ikke tidligere havde fået qHPV-vaccinen i andre studier, hvorimod GMT'erne over for HPV-type 31, 33, 45, 52 og 58 var lavere.
English: GMT Ratio
Danish: GMT Forhold
English: Gardasil 9 suspension for injection:
Danish: Gardasil 9 injektionsvæske, suspension:
English: HPV 31-, 33-, 45-, 52-, 58-related CIN2
Danish: HPV 31-, 33-, 45-, 52-, 58-relateret CIN2
English: HPV 31-, 33-, 45-, 52-, 58-related CIN3
Danish: HPV 31-, 33-, 45-, 52-, 58-relateret CIN3
English: Anti-HPV 11 9 to 15 year old girls
Danish: Anti-HPV 11
English: How to store Gardasil 9
Danish: Sådan får du Gardasil 9
English: Gardasil 9 suspension for injection in a pre-filled syringe:
Danish: Gardasil 9 injektionsvæske, suspension i fyldt injektionssprøjte:
English: Anti-HPV 18 9 to 15 year old girls
Danish: Anti-HPV 18
English: What Gardasil 9 is and what it is used for What you need to know before you or your child receive Gardasil 9 How Gardasil 9 is given
Danish: Det skal du vide, før du eller dit barn får Gardasil 9 Sådan får du Gardasil 9
English: Anti-HPV 16 9 to 15 year old girls
Danish: Anti-HPV 16
English: - If you have any further questions, please ask your doctor, pharmacist or nurse.
Danish: - Spørg lægen, apotekspersonalet eller sundhedspersonalet, hvis der er mere, du vil vide.
English: The PPE population consisted of individuals who received all 3 vaccinations with qHPV vaccine in the base study within 1 year of enrolment without major deviations from the study protocol, were seronegative to the relevant HPV type(s) (types 6, 11, 16, and 18) prior to dose 1, and among subjects 16 years and older at enrolment in the base study, PCR negative to the relevant HPV type(s) prior to dose 1 through one month postdose 3 (Month 7).
Danish: De var desuden seronegative over for den/de relevante HPV-type(r) (type 6, 11, 16 og 18) før dosis 1, og blandt forsøgspersoner, der var 16 år og derover ved inklusionen i basisstudiet, bestod PPE-populationen af personer, der var PCR-negative over for den/de relevante HPV-type(r) før dosis 1 til og med 1 måned efter dosis 3 (måned 7).
English: The PPE population consisted of individuals: - who received all 3 vaccinations within 1 year of enrolment, without major deviations from the study protocol, - who were seronegative to the relevant vaccine HPV type(s) prior to dose 1 and among women aged 16 to 26 years, PCR negative to the relevant vaccine HPV type(s) prior to dose 1 through one month postdose 3 (Month 7).
Danish: - var seronegative over for den/de relevante vaccine-HPV-type(r) før dosis 1 og blandt kvinder i alderen 16 til 26 år, var PCR-negative over for den/de relevante vaccine-HPV-type(r) før dosis 1 og til og med en måned efter dosis 3 (måned 7).
English: Anti-HPV 6 9 to 15 year old girls
Danish: Anti-HPV 6
English: The full EPAR for Fotivda can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Danish: Den fuldstændige EPAR for Fotivda findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This is a summary of the European public assessment report (EPAR) for Fotivda.
Danish: Dette dokument er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Fotivda.
English: It contains the active substance tivozanib.
Danish: Det indeholder det aktive stof tivozanib.
English: The usual dose is one 1,340-microgram capsule once a day for three weeks, followed by a week when the patient does not take any capsules.
Danish: Den sædvanlige dosis er en 1 340 mikrogram kapsel én gang dagligt i tre uger, efterfulgt af en uge, hvor patienten ikke tager nogen kapsler.
English: Fotivda is available as capsules (890 and 1,340 micrograms).
Danish: Fotivda fås som kapsler (890 og 1 340 mikrogram).
English: Other information about Fotivda
Danish: Andre oplysninger om Fotivda
English: The most common side effects are high blood pressure (which occurs in almost half of patients) and voice changes, tiredness and diarrhoea (which occur in about a quarter of patients).
Danish: De hyppigste bivirkninger er højt blodtryk (som optræder hos næsten halvdelen af patienterne) og stemmeforandringer, træthed og diarré (som optræder hos ca. en fjerdedel af patienterne).
English: What is Fotivda and what is it used for?
Danish: Hvad er Fotivda, og hvad anvendes det til?
English: On the whole, its side effects are in line with what is expected of a medicine of its class (VEGF inhibitors).
Danish: I sin helhed er dets bivirkninger i overensstemmelse med, hvad der forventes af et lægemiddel i denne kategori (VEGF-inhibitorer).
English: If the patient has troublesome side effects, the doctor may decide to switch to the lower-strength 890-microgram capsules or interrupt treatment.
Danish: Hvis patienten har generende bivirkninger, kan lægen beslutte at skifte til kapslerne med lavere styrke, 890 mikrogram, eller afbryde behandlingen.
English: The patients should continue repeating this 4-week course for as long as the disease does not get worse or until side effects become unacceptable.
Danish: Patienten bør gentage dette 4-ugers forløb så længe, sygdommen ikke bliver værre, eller indtil bivirkningerne bliver uacceptable.
English: It is not intended to provide practical advice on how to use Fotivda.
Danish: Det er ikke en praktisk vejledning i, hvordan Fotivda bør anvendes.
English: Why is Fotivda approved?
Danish: Hvorfor blev Fotivda godkendt?
English: The most important serious side effect with Fotivda is high blood pressure.
Danish: De hyppigste alvorlige bivirkninger ved Fotivda er højt blodtryk.
English: The most common side effects with Fotivda are considered manageable, although they may affect the patient's quality of life.
Danish: De hyppigst forekommende bivirkninger ved Fotivda anses for overkommelige, selv om de kan påvirke patientens livskvalitet.
English: A main study of 517 patients with advanced renal cell carcinoma that had either come back or spread to other parts of the body has shown that Fotivda can help stop the disease from getting worse.
Danish: En hovedundersøgelse med 517 patienter med fremskreden renalcellecarcinom, som enten havde fået tilbagefald eller oplevet spredning til andre dele af kroppen, har vist, at Fotivda kan forhindre sygdommen i at blive værre.
English: Fotivda can only be obtained with a prescription, and treatment should be supervised by a doctor with experience of treating cancers.
Danish: Fotivda udleveres kun efter recept, og behandlingen bør overvåges af en læge med erfaring i behandling af kræft.
English: What measures are being taken to ensure the safe and effective use of Fotivda?
Danish: Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af Fotivda?
English: By blocking this protein, tivozanib stops the formation of new blood vessels that the tumour needs, thereby cutting off its blood supply and reducing the growth of the cancer.
Danish: Ved at blokere dette protein stopper tivozanib dannelsen af nye blodkar, som tumoren har brug for, og afskærer derved blodtilførslen dertil og nedsætter væksten af kræften.
English: The European Medicines Agency therefore concluded that the benefits of Fotivda outweighed its risk and recommended that it be granted authorisation in the EU.
Danish: Det Europæiske Lægemiddelagentur konkluderede derfor, at fordelene ved Fotivda opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
English: Fotivda may be used in previously untreated patients or in those whose disease has got worse despite treatment with another medicine working in a different way.
Danish: Fotivda kan anvendes af patienter, der ikke tidligere har været behandlet, eller af patienter, hvis sygdom er forværret på trods af behandling med et andet lægemiddel, der fungerer på en anden måde.
English: What are the risks associated with Fotivda?
Danish: Hvilke risici er der forbundet med Fotivda?
English: The active substance in Fotivda, tivozanib, works by blocking the activity of proteins known as VEGF, which stimulate the formation of new blood vessels.
Danish: Det aktive stof i Fotivda, tivozanib, fungerer ved at blokere for aktiviteten af proteiner af typen VEGF, der stimulerer dannelsen af nye blodkar.
English: For more information about treatment with Fotivda, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Danish: Hvis du ønsker yderligere oplysninger om behandling med Fotivda, kan du læse indlægssedlen (også en del af denne EPAR) eller kontakte din læge eller dit apotek.
English: In this study, patients taking Fotivda lived for longer without their disease worsening (12 months) than those given another approved medicine sorafenib (9 months).
Danish: I denne undersøgelse levede de patienter, der tog Fotivda, længere uden at deres sygdom blev forværret (12 måneder) sammenlignet med dem, der fik et andet godkendt lægemiddel, sorafenib (9 måneder).
English: Fotivda is a medicine for treating adults with advanced renal cell carcinoma (a kidney cancer).
Danish: Fotivda er et lægemiddel til behandling af voksne med fremskreden renalcellecarcinom (en form for nyrekræft)
English: A main study showed that Fotivda increased the time it took for the disease to get worse by almost 3 months when compared with another approved medicine sorafenib.
Danish: En hovedundersøgelse viste, at Fotivda forlængede den tid, det tog for sygdommen at blive værre, med næsten tre måneder sammenlignet med et andet godkendt lægemiddel, sorafenib.
English: Patients must not take St John's wort (a herbal remedy for depression) during treatment with Fotivda.
Danish: Patienterne må ikke tage perikon (et plantelægemiddel mod depression), når de er i behandling med Fotivda.
English: For practical information about using Fotivda, patients should read the package leaflet or contact their doctor or pharmacist.
Danish: Hvis du ønsker praktisk vejledning om anvendelsen af Fotivda, kan du læse indlægssedlen eller kontakte din læge eller dit apotek.
English: What benefits of Fotivda have been shown in studies?
Danish: Hvilke fordele viser undersøgelserne, at der er ved Fotivda?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Fotivda have been included in the summary of product characteristics and the package leaflet.
Danish: Der er anført anbefalinger og forholdsregler i produktresuméet og indlægssedlen, som patienter og sundhedspersonale skal følge for at sikre risikofri og effektiv anvendelse af Fotivda.
English: How is Fotivda used?
Danish: Hvordan anvendes Fotivda?
English: How does Fotivda work?
Danish: Hvordan virker Fotivda?
English: More information on Uptravi can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Danish: Yderligere oplysninger om Uptravi findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: This also applies to any changes in the dose.
Danish: Dette gælder også ved ændring af dosen.
English: This could lead to patients receiving either too much (overdose) or too little (underdose) of the medicine.
Danish: Dermed kan patienterne få enten for meget (overdosis) eller for lidt (underdosis) af medicinen.
English: • The first dose of Uptravi should always be taken in the evening.
Danish: • Den første dosis af Uptravi skal altid tages om aftenen.
English: Underdosing may result in lack of effect whereas overdosing may lead to side effects such as headache, diarrhoea, nausea and vomiting.
Danish: Underdosering kan medføre manglende virkning, hvorimod overdosering kan medføre bivirkninger såsom hovedpine, diarré, kvalme og opkastning.
English: Measures to prevent medication errors due to weekly dose increases during initial titration phase
Danish: Foranstaltninger til at forhindre fejlmedicinering i forbindelse med ugentlige dosisforøgelser i den indledende titreringsfase
English: When the dose is changed, the new dose should also be first taken in the evening.
Danish: Når dosen ændres, bør den nye dosis også tages om aftenen første gang.
English: Educational brochure for healthcare professionals and diary for patients using Uptravi
Danish: Informationsbrochure til sundhedspersoner og dagbog til patienter, der bruger Uptravi
English: Treatment with Uptravi includes an initial titration phase, whereby the patient receives a low starting dose which is gradually increased over several weeks to a maintenance dose, which is continued longterm.
Danish: Behandling med Uptravi omfatter en indledende titreringsfase, hvor patienten modtager en lav startdosis, der gradvist øges over flere uger op til en vedligeholdelsesdosis, der fastholdes i lang tid.
English: In addition, prescribers will only be able to prescribe Uptravi once they have registered with the company that markets Uptravi and received appropriate information on the safe and effective use of Uptravi.
Danish: Derudover vil de ordinerende læger først kunne udskrive Uptravi, når de er blevet registreret hos den virksomhed, der markedsfører Uptravi, og har modtaget den relevante information om sikker og effektiv brug af lægemidlet.
English: Patients will be given a diary to help them remember which dose to take.
Danish: Patienterne vil få en dagbog, der skal hjælpe dem med at huske, hvilken dosis de skal tage.
English: The fact that Uptravi is available in different strengths and that the dose is changed usually weekly during the titration phase may lead to confusion and errors by patients when taking the medicine.
Danish: Det faktum, at Uptravi fås i forskellige styrker, og at dosen typisk skifter hver uge i titreringsfasen, kan medføre forvirring og fejl hos patienterne, når de skal tage deres medicin.
English: This leads to high blood pressure in the vessels taking blood from the heart to the lungs and reduces the amount of oxygen that can get into the blood in the lungs, making physical activity more difficult.
Danish: Det giver forhøjet blodtryk i de kar, der fører blodet fra hjertet til lungerne, og reducerer den mængde ilt, der kommer ind i blodet i lungerne, hvilket vanskeliggør fysisk aktivitet.
English: Healthcare professionals expected to prescribe and dispense Uptravi (selexipag) will be given an educational brochure to ensure that the medicine is used correctly.
Danish: De sundhedspersoner, der forventes at ordinere og udlevere Uptravi (selexipag), vil få udleveret en informationsbrochure for at sikre, at medicinen bruges korrekt.
English: It is available as tablets to be taken by mouth.
Danish: Lægemidlet fås som tabletter, der tages gennem munden.
English: In case you are only using the 200 microgram strength, the diary pages look as follows:
Danish: Hvis du kun bruger 200 mikrogram-styrken, ser siderne i dagbogen sådan her ud:
English: Uptravi is available in different strengths (200; 400; 600; 800; 1,000; 1,200; 1,400 and 1,600 micrograms).
Danish: Uptravi fås i forskellige styrker (200, 400, 600, 800, 1 000, 1 200, 1 400 og 1 600 mikrogram).
English: The 200 strength is used to step the dose up and down slowly during titration.
Danish: Styrken på 200 mikrogram anvendes til at trappe dosis langsomt op og ned under titrering.
English: Once you have gone through the 4 steps of increasing the dose and are at step 5, you will be taking both the 200 microgram and the 800 microgram strengths at the same time.
Danish: Når du har været gennem de fire trin med øgning af dosen og er på trin 5, skal du tage både 200 mikrogram- og 800 mikrogram-tabletten på samme tid.
English: • Before prescribing or dispensing Uptravi, healthcare professionals should give patients a titration guide and diary to help them keep track of the number of tablets they take.
Danish: • Før ordinering og udlevering af Uptravi skal sundhedspersonerne give patienterne en titreringsvejledning og en dagbog, der kan hjælpe dem med at holde styr på det antal tabletter, som de skal tage.